General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

On Jan 15, Pfizer Inc. ( PFE, Financial) announced to sale of about 700 million ordinary shares of Haleon plc through a ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole Raleigh sat down with Pfizer’s ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.